Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyAmyloidosisTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
August 9
 · 
Reactions
A MyAmyloidosisTeam Member

I understand. My original diagnosis was wild type and my insurance denied Amvuttra. Now that we have genetic results indicating it is hATTR my doctor is resubmitting for authorization. If you have wt they should still put you on one of the medications to slow progression of the disease. I’m fortunate to have an amyloidosis center at the hospital near me which helps get to doctors who specialize in this rare disease. I’m now seeing a neurologist who knows about the disease. For nearly two years they simply diagnosed me with neuropathy for unknown cause. Good luck on your treatment journey!

August 15
A MyAmyloidosisTeam Member

We are at the mercy of pharmaceutical and insurance companies.

August 10
MyAmyloidosisTeam

That frustration makes complete sense — wanting to get ahead of potential heart damage rather than waiting for it to worsen is a very reasonable way of thinking about your care.

The key issue is that Amvuttra (vutrisiran) is currently FDA-approved specifically for the polyneuropathy form of hereditary ATTR (hATTR) Show Full Answer

That frustration makes complete sense — wanting to get ahead of potential heart damage rather than waiting for it to worsen is a very reasonable way of thinking about your care.

The key issue is that Amvuttra (vutrisiran) is currently FDA-approved specifically for the polyneuropathy form of hereditary ATTR (hATTR) amyloidosis — not for wild-type ATTR (wtATTR). Since wtATTR is not an inherited (gene mutation) form of the disease, it falls outside the current approved use of Amvuttra. FDA approval matters a great deal here because:

- Insurance companies typically won't cover a medication used "off-label" (outside its approved use)
- Doctors can face liability concerns prescribing outside approved indications
- Clinical trial data supporting its use in wtATTR with polyneuropathy is still limited

That said, research is ongoing and approvals do evolve. It's absolutely worth having a direct conversation with your specialist about whether any clinical trials or expanded access programs might be available to you, especially given your existing AFib.

August 9
A MyAmyloidosisTeam Member

Thanks Greg. It appears I need a doctor to say I have cardiomyopathy to get Amvutra. I want it for the polyneuropathy but it is only FDA approved for those with hATTRpn. I have wtATTRpn which does not frequently occur and therefore Amvutra is not FDA approved for wild type ATTR with polyneuropathy. Crazy. My feet are numb.

August 15
A MyAmyloidosisTeam Member

Carol
I would suggest a second opinion from a cardiologist who specializes in amyloidosis. You have to be your own advocate. I had poly neuropathy about 2 to 3 years before my cardiologist diagnosed me with ATTR CM. He immediately put me on Vyndamax. After genetic testing confirmed hATTR he’s now working on prior authorization for Amvuttra. You should research amyloidosis doctors near you. Good luck and don’t give up!

August 15

Related Questions

View All
A MyAmyloidosisTeam Member asked a question 💭
Norwich, UK

Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In